DB:YOU
DB:YOUSpecialty Retail

ABOUT YOU (DB:YOU): Ongoing Losses Challenge Growth-Focused Bullish Narratives Despite Forecast-Beating Revenue Outlook

ABOUT YOU Holding (DB:YOU) continues to operate at a loss, with forecasts indicating ongoing unprofitability for at least the next three years. Over the past five years, losses have been trimmed by 0.5% per year, while revenue is projected to grow 6.33% annually, comfortably outpacing the broader German market’s 6% yearly forecast. For investors, this means weighing a robust top-line growth trajectory against persistent bottom-line challenges as the company’s share price trades at €6.63,...
XTRA:BAYN
XTRA:BAYNPharmaceuticals

Does Bayer’s 40% Rally Signal a Turning Point After Legal Settlement News?

Thinking about what to do with Bayer stock? You are definitely not alone. With a year-to-date gain of 40.6%, Bayer has surprised many investors and grabbed the attention of market watchers who remember its far rockier past. Over the last three years, shares are still down a dramatic 42.4%, but this recent resurgence has some asking whether the tide has finally turned. Bayer’s longer-term story has been marked by volatility, with notable dips over the last five years and a relatively modest...
XTRA:BMW
XTRA:BMWAuto

BMW (XTRA:BMW) Valuation: Is There Untapped Value After Recent Share Price Dip?

Bayerische Motoren Werke (XTRA:BMW) shares have shifted modestly over the past month, slipping around 6%. Investors are keeping an eye on recent performance trends to gauge what might be next for the automaker’s stock price. See our latest analysis for Bayerische Motoren Werke. While BMW’s share price has dipped roughly 10% over the past week and remains slightly down for the month, the bigger picture reveals continued strength. Investors have seen a 10% total shareholder return over the past...
XTRA:GXI
XTRA:GXILife Sciences

Could Gerresheimer (XTRA:GXI) Leverage FDA-Approved Home-Infusion Device to Strengthen its Medtech Differentiation?

On October 13, 2025, SQ Innovation announced that the US FDA had granted approval for Lasix ONYU, a combination product for edema in congestive heart failure, which features Gerresheimer’s on-body infusor device for at-home subcutaneous drug delivery. This milestone showcases Gerresheimer’s advanced expertise in drug delivery technology and its integral role as a full-service partner in the rapidly evolving medtech space. We will examine how FDA approval of a home-infusion device may...
XTRA:M12
XTRA:M12Healthcare

Undiscovered Gems In Europe Featuring 3 Promising Small Caps

As European markets face headwinds from political turmoil and trade tensions, the pan-European STOXX Europe 600 Index has recently seen a decline following record highs. Despite these challenges, small-cap stocks can often present unique opportunities for investors willing to explore beyond the well-trodden paths of major indices, as they may offer growth potential driven by innovation and niche market positions.
XTRA:EKT
XTRA:EKTElectrical

Energiekontor (XTRA:EKT): Assessing Valuation After Earnings Guidance Cut and Project Delays

Energiekontor (XTRA:EKT) has cut its 2025 earnings guidance, citing delays in German projects as well as regulatory and operational changes affecting British wind developments. This shift has pushed expected earnings into 2026, shaking investor confidence. See our latest analysis for Energiekontor. Following the forecast revision, Energiekontor’s share price slumped nearly 19% in a single day, capping off a tough stretch where the 1-year total shareholder return is down almost 23%. With...
XTRA:DTE
XTRA:DTETelecom

European Dividend Stocks To Watch In October 2025

As European markets experience a pullback from record highs amid political turmoil in France and renewed global trade tensions, investors are increasingly turning their attention to dividend stocks for stability and income. In such uncertain times, a good dividend stock is often characterized by its consistent payout history and resilience to economic fluctuations, making it an attractive option for those seeking steady returns amidst market volatility.